Hormone management of trans women

@article{Coxon2018HormoneMO,
  title={Hormone management of trans women},
  author={Jonny Coxon and Leighton J. Seal},
  journal={Trends in Urology \& Men's Health},
  year={2018},
  volume={9}
}
  • J. CoxonL. Seal
  • Published 1 November 2018
  • Medicine
  • Trends in Urology & Men's Health
In the previous issue, the authors introduced some principles underlying the medical management of transgender people, before focusing on trans men. In this article they look at the hormonal management of men transitioning to a female gender. 
1 Citations

Hormone management of trans men

How hormonal treatments are used in trans men undergoing transition is described and the vital role of primary care in managing ongoing prescribing and monitoring of treatment is discussed.

References

SHOWING 1-10 OF 23 REFERENCES

Hormone management of trans men

How hormonal treatments are used in trans men undergoing transition is described and the vital role of primary care in managing ongoing prescribing and monitoring of treatment is discussed.

Mortality and morbidity in transsexual subjects treated with cross‐sex hormones

Investigation of mortality and morbidity figures in a large group of transsexual subjects receiving cross‐sex hormone treatment finds that the optimum steroid hormone treatment regimes for transsexual subjects has not yet been established.

Effects of sex steroids on components of the insulin resistance syndrome in transsexual subjects

objective Sex differences are found in most components of the insulin resistance syndrome and the associated cardiovascular risk profile. These differences are attributed to sex‐specific sex steroid

Predictive markers for mammoplasty and a comparison of side effect profiles in transwomen taking various hormonal regimens.

Self-medication with estrogen is significantly more likely to result in a later request for mammoplasty than is treatment prescribed by licensed practitioners and CEE treatment is associated with a higher incidence of thromboembolism than treatment with other estrogen types.

Sex Steroids and Cardiovascular Outcomes in Transgender Individuals: A Systematic Review and Meta‐Analysis

Low‐quality evidence suggests that sex steroid therapy may increase LDL‐C and TG levels and decrease HDL‐C level in FTM individuals, whereas oral estrogens may increase TG levels in MTF individuals.

Prostate cancer incidence in orchidectomised male‐to‐female transsexual persons treated with oestrogens

Male‐to‐female transsexual persons (MtoF) undergoing treatment with antiandrogens and oestrogens followed by bilateral orchiectomy between 1975 and 2006 were reviewed, finding PCa in this large MtoF population was rare.

ENDOCRINE TREATMENT OF GENDER-DYSPHORIC/GENDER-INCONGRUENT PERSONS: AN ENDOCRINE SOCIETY CLINICAL PRACTICE GUIDELINE.

  • W. HembreeP. Cohen-Kettenis G. T’Sjoen
  • Medicine
    Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • 2017
This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation approach to describe the strength of recommendations and the quality of evidence about the effect of sex steroids on bone health in transgender individuals.

TESTOSTERONE LEVELS ACHIEVED BY MEDICALLY TREATED TRANSGENDER WOMEN IN A UNITED STATES ENDOCRINOLOGY CLINIC COHORT.

Among a cohort of transgender women treated with spironolactone and estrogen, the highest suppressing quartile could reliably achieve testosterone levels in the female range at virtually all times, while the second highest suppressing Quartile could not achieve female levels but remained below the male range virtually all the time.

Clinical review: Breast development in trans women receiving cross-sex hormones.

The available evidence suggests that breast development is insufficient for the majority of trans women and that type and dosage of hormonal therapy seem not to have an important role on final breast size.

Physical and hormonal evaluation of transsexual patients: A longitudinal study

Based on the data generated by this study, it is recommended as hormonal therapy 0.1–0.5 mg/day of ethinyl estradiol or 7.5–10 mg/ day of conjugated estrogen for male-to-female transsexuals, and intramuscular testosterone cypionate, 200 mg every 2 weeks, for female- to-male transsexuals.